Monoclonal antibodies
Follow Monoclonal antibodies on Notably News to receive short updates to your email — rarely!
We include updates on Dupilumab, Adalimumab, Denosumab, Infliximab, Risankizumab, Evolocumab, Secukinumab, Omalizumab, Vedolizumab, Guselkumab, Galcanezumab, Tocilizumab, Lokivetmab, Lecanemab, Ustekinumab, TNF inhibitor ... and more.
| March 2024 |
Monoclonal antibody
US FDA granted emergency use authorization to pemivibart, a monoclonal antibody drug, for pre-exposure prophylaxis in moderately to severely immunocompromised individuals against COVID-19.
|
| July 2023 |
Monoclonal antibody therapy
The FDA granted full approval to Lecanemab (commercial name Leqembi) for the treatment of Alzheimer's Disease, marking a significant milestone in monoclonal antibody therapy for the condition.
|
| 2022 |
Monoclonal antibody
Cochrane reviews found insufficient evidence for using neutralizing monoclonal antibodies to treat COVID-19 infections, with studies limited to existing COVID-19 variants.
|
| 2021 |
Monoclonal antibody
Cochrane reviews found insufficient evidence for using neutralizing monoclonal antibodies to treat COVID-19 infections in unvaccinated individuals.
|
| September 2021 |
Monoclonal antibody
Biden administration purchased billions of dollars worth of Regeneron monoclonal antibodies at $2,100 per dose to address COVID-19 treatment shortages.
|
| 2020 |
Monoclonal antibody
US Food and Drug Administration granted emergency use authorizations for monoclonal antibody therapies bamlanivimab/etesevimab and casirivimab/imdevimab to reduce COVID-19 hospitalizations, emergency room visits, and deaths.
|
| June 2019 |
Monoclonal antibody therapy
Polatuzumab vedotin (Polivy) approved, targeting CD79B.
|
| September 2018 |
Monoclonal antibody therapy
Cemiplimab (Libtayo) approved, targeting PD-1.
|
| September 2018 |
Monoclonal antibody therapy
Moxetumomab pasudotox (Lumoxiti) approved, targeting CD22.
|
| August 2018 |
Monoclonal antibody therapy
Mogamulizumab (Poteligeo) approved, targeting CCR4.
|
| December 2012 |
Monoclonal antibody therapy
DIAN-TU study launched, focusing on young patients with genetic mutations that are risk factors for Alzheimer's Disease. The study investigates Solanezumab and Gautenerumab as potential preventive treatments.
|
This contents of the box above is based on material from the Wikipedia articles Monoclonal antibody therapy & Monoclonal antibody, which are released under the Creative Commons Attribution-ShareAlike 4.0 International License.